PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study
Status:
Terminated
Trial end date:
2020-07-27
Target enrollment:
Participant gender:
Summary
The main objective of this clinical trial is to study the efficacy and safety of cobomarsen
(also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis
fungoides (MF) subtype in subjects who have confirmed disease progression following treatment
with vorinostat in the SOLAR clinical study (MRG106-11-201). Cobomarsen is designed to
inhibit the activity of a molecule called miR-155 that may be important to the growth and
survival of MF cancer cells.
The effects of treatment will be measured based on changes in skin lesion severity,
disease-associated symptoms, and quality of life, as well as the length of time that the
subject's disease remains stable or improved, without evidence of disease progression. The
safety and tolerability of cobomarsen will be assessed based on the frequency and severity of
observed side effects.